Ian Judson mainly focuses on Internal medicine, Surgery, Sarcoma, Chemotherapy and Oncology. The various areas that Ian Judson examines in his Internal medicine study include Gastroenterology and Pathology. The concepts of his Gastroenterology study are interwoven with issues in Pharmacokinetics, Neutropenia, Toxicity, Asymptomatic and Rash.
His work deals with themes such as Cancer, Radiation therapy and Imatinib mesylate, which intersect with Sarcoma. His biological study spans a wide range of topics, including Pharmacodynamics and Pharmacology. His Oncology research is multidisciplinary, incorporating elements of Vincristine, Prospective cohort study and Liposarcoma.
Ian Judson mostly deals with Internal medicine, Surgery, Sarcoma, Oncology and Chemotherapy. His studies in Internal medicine integrate themes in fields like Gastroenterology and Soft tissue sarcoma. His research in Sarcoma intersects with topics in Progression-free survival and Leiomyosarcoma.
His Oncology research includes themes of Progressive disease, Disease, Phases of clinical research, Randomized controlled trial and Placebo. Ian Judson combines subjects such as Pharmacokinetics, Radiation therapy, Toxicity and Urology with his study of Chemotherapy. His Cancer study integrates concerns from other disciplines, such as Cancer research and Pharmacology.
His primary areas of study are Internal medicine, Sarcoma, Oncology, Surgery and Soft tissue sarcoma. His research integrates issues of Cancer, Clinical trial and GiST in his study of Sarcoma. His Oncology research also works with subjects such as
His work in Surgery is not limited to one particular discipline; it also encompasses Urology. His Soft tissue sarcoma research is multidisciplinary, relying on both Physical therapy, Leiomyosarcoma and Doxorubicin. His Chemotherapy study combines topics in areas such as Radiation therapy and Disease.
The scientist’s investigation covers issues in Surgery, Sarcoma, Internal medicine, Oncology and Ifosfamide. His Sarcoma research includes elements of Radiation therapy, GiST and MEDLINE. The GiST study combines topics in areas such as Clinical trial, Cohort study, Imatinib mesylate, Rectum and Pelvic exenteration.
His Internal medicine study combines topics from a wide range of disciplines, such as Soft tissue sarcoma and Gastroenterology. The various areas that Ian Judson examines in his Oncology study include Chondrosarcoma, Cancer registry and Primitive neuroectodermal tumor. His Ifosfamide research is multidisciplinary, relying on both Urology, Cyclophosphamide and Doxorubicin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein.
The Lancet (2006)
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A H Calvert;D R Newell;L A Gumbrell;S O'Reilly.
Journal of Clinical Oncology (1989)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*
Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne.
The Lancet (2004)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim.
The Lancet (2012)
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Allan T van Oosterom;Ian Judson;Jaap Verweij;Sigrid Stroobants.
The Lancet (2001)
Soft-Tissue Sarcomas in Adults
Matthew A Clark;Cyril Fisher;Ian Judson;J Meirion Thomas.
The New England Journal of Medicine (2005)
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay.
Journal of The National Comprehensive Cancer Network (2007)
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
P.G. Casali;N. Abecassis;S. Bauer;R. Biagini.
Annals of Oncology (2018)
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi.
Annals of Oncology (2005)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer.
European Journal of Cancer (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: